Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice

Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice

Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is hampered by cardiotoxicity, defined as a left ventricular ejection fraction (LVEF) decline with a reported incidence r...

Full description

Bibliographic Details
Main Authors: Nathalie I. Bouwer, Agnes Jager, Crista Liesting, Marcel J.M. Kofflard, Jasper J. Brugts, Jos J.E.M. Kitzen, Eric Boersma, Mark-David Levin
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:Breast
Subjects:
Trastuzumab
Cardiotoxicity
Cardiac monitoring
Biomarkers
Speckle tracking echocardiography
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620300928

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620300928

Similar Items